Fig. 1
CLDN7 was downregulated in ccRCC patients and associated with poor prognosis. (A) a. Microarray chip assay showed CLDN7 expression in 6 ccRCC tissues and paired adjacent normal kidney tissues from Peking University First Hospital. b. Comparison of CLDN7 mRNA expression between normal kidney and ccRCC tissues. c. Comparison of CLDN7 mRNA expression between normal kidney and non-ccRCC tissues. d. Comparison of CLDN7 mRNA expression among normal kidney, ccRCC, chRCC and pRCC tissues. (B) a. Relative expression of CLDN7 mRNA in ccRCC cell lines compared with normal kidney cell HEK-293. b. Relative expression of CLDN7 mRNA in 12 paired ccRCC tissues and adjacent normal kidney tissues. (C) Western blot showed CLDN7 protein expression in RCC cell lines and HEK-293. (D) Immunohistochemistry staining analysis of CLDN7 protein expression in 144 RCC tissues and adjacent normal kidney tissues (tissue microarray, total 129 ccRCC, 15 non-ccRCC and 145 normal kidney tissues). Immunostaining intensity was graded as no stained, weakly stained, moderately stained and strongly stained. (E) The representative immunostaining of CLDN7 in normal kidney, ccRCC, pRCC and chRCC tissues (Scale bar, 100 μm). (F) Kaplan-Meier curves of overall survival time between low (n = 473) and high (n = 59) CLDN7 mRNA expression group in 534 ccRCC patients from TCGA. The cut-off value was the mean of CLDN7 mRNA expression in 129 normal kidney tissues. (G) Kaplan-Meier curves of disease free survival time in 4 respective CLDN7 protein expression group including No stained (n = 61), Weakly stained (n = 54), Moderately stained (n = 21) and Strongly stained (n = 8) in 144 RCC patients from our hospital. Results that were expressed as the mean ± SD from at least three independent experiments. N.S refers to not significant. * refers to p < 0.05. ** refers to p < 0.01